Cases & Deals

  • Home
  • Practices
  • Rigel develops global patent portfolio related to small molecule inhibitors for treatment of hematological and oncological conditions

Share

Rigel develops global patent portfolio related to small molecule inhibitors for treatment of hematological and oncological conditions

June 2024

Client(s) Rigel Pharmaceuticals, Inc.

Jones Day is representing Rigel Pharmaceuticals, Inc. ("Rigel") in connection with the management of global patent portfolios related to TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult chronic immune thrombocytopenia, REZLIDHIA® (olutasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia, GAVRETO® (pralsetinib) for the treatment of rearranged during transfection (RET) fusion-positive non-small cell lung cancer and thyroid cancer, and IRAK1/4 inhibitors for the treatment of inflammatory conditions. Rigel is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.